nct_id: NCT05800665
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-04-05'
study_start_date: '2023-05-02'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: RO7656594'
long_title: A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study
  Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With
  Advanced or Metastatic Prostate Cancer
last_updated: '2025-10-30'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Genentech, Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 210
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Key Inclusion Criteria:'
- "1. Eastern Cooperative Oncology Group (ECOG) performance status \u22641."
- 2. Metastatic prostate adenocarcinoma without small-cell carcinoma or neuroendocrine
  features.
- 3. Prior therapy with a second-generation androgen receptor (AR)-targeted therapy
  (e.g., abiraterone, enzalutamide, apalutamide, darolutamide).
- 4. Prior therapy with a taxane regimen or are considered ineligible for treatment
  with a taxane regimen or have refused treatment with a taxane regimen, unless otherwise
  specified.
- '5. For participants with a known pathogenic breast cancer gene 1 (BRCA1) or BRCA2
  mutation: prior therapy with a poly (adenosine diphosphate (ADP)-ribose) polymerase
  (PARP) inhibitor, or are considered ineligible for treatment with a PARP inhibitor,
  if such therapy is approved and available.'
- 'Exclude - Key Exclusion Criteria:'
- Exclude - 1. Treatment with any approved systemic anti-cancer therapy within 14
  days or 5 drug elimination half-lives (whichever is longer, not to exceed 28 days)
  prior to the first study treatment.
- Exclude - 2. Treatment with any investigational agent within 28 days prior to the
  first study treatment.
- Exclude - 3. Treatment with any previous AR protein degrader.
- Exclude - 4. Untreated central nervous system (CNS) metastases or leptomeningeal
  disease.
- 'Exclude - Note: Other protocol specified inclusion/exclusion criteria may apply.'
short_title: A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594
  In Participants With Advanced or Metastatic Prostate Cancer
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Genentech, Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics,
  and preliminary activity of RO7656594 in participants with advanced or metastatic
  prostate cancer. It will also identify recommended doses and regimens for RO7656594
  for subsequent studies.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Stage 1: Dose Escalation'
      arm_internal_id: 0
      arm_description: Participants will receive RO7656594 administered at a specified
        dose on specific days in each 28-day cycle. The dose will be increased in
        successive cohorts until a study-specific threshold is reached.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: RO7656594'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Stage 2: Expansion'
      arm_internal_id: 1
      arm_description: Participants will receive RO7656594 at or below the maximum
        tolerated dose (MTD) or maximum administered dose (MAD).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: RO7656594'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - and:
        - or:
          - clinical:
              oncotree_primary_diagnosis: Prostate Adenocarcinoma
          - clinical:
              oncotree_primary_diagnosis: Prostate Neuroendocrine Carcinoma
          - clinical:
              oncotree_primary_diagnosis: Prostate Small Cell Carcinoma
        - clinical:
            age_numerical: '>=18'
            gender: Male
            disease_status:
            - Metastatic
      - or:
        - genomic:
            hugo_symbol: BRCA1
            variant_category: Mutation
        - genomic:
            hugo_symbol: BRCA2
            variant_category: Mutation
